In the wake of the increase in Current Liabilities in the second quarter 2026, Quick Ratio fell to 1.39 below Omeros Corporation average.

Within Major Pharmaceutical Preparations industry 326 other companies have achieved higher Quick Ratio than Omeros in second quarter 2026. While Quick Ratio total ranking has improved so far during the Q2 2026 to 1325, from total ranking in the first quarter 2026 at 1615.

Explain Quick Ratio?
How much Cash & cash equivalents OMER�s has?
What are OMER�s Current Liabilities?

Select the Comparisons :

None ▼

Select the Ratio:

Quick Ratio ▼

None ▼

Quick Ratio ▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

OMER Quick Ratio	(Jun 30 2026) Q2	(Mar 31 2026) Q1	(Dec 31 2025) Q4	(Sep 30 2025) Q3	(Jun 30 2025) Q2
Y / Y Current Liabilities Change	11.06 %	-28.57 %	-0.4 %	45.18 %	43.76 %
Y / Y Cash & cash equivalent Change	359.06 %	158.18 %	90.61 %	-70.7 %	-81.91 %
Quick Ratio MRQ	1.39	2.28	2.17	0.45	0.34
OMER's Total Ranking	# 1325	# 1615	# 3191	# 3546	# 2867
Seq. Current Liabilities Change	59.75 %	-24.95 %	-1.92 %	-5.55 %	2.74 %
Seq. Cash & cash equivalent Change	-2.49 %	-21.24 %	376.11 %	25.54 %	-45.16 %

Quick Ratio second quarter 2026 Company Ranking
Within:	No.
Major Pharmaceutical Preparations Industry	# 327
Healthcare Sector	# 579
Overall Market	# 1699

Quick Ratio Statistics
High	Average	Low
5.59	2.09	0.34
(Sep 30 2022)		(Jun 30 2025)

Financial Statements
Omeros's Current Liabilities	$ 95 Millions	Visit OMER's Balance sheet
Omeros's Cash & cash equivalent	$ 132 Millions	Visit OMER's Balance sheet
Source of OMER's Sales		Visit OMER's Sales by Geography

Cumulative Omeros's Quick Ratio

OMER's Quick Ratio for the trailling 12 Months

OMER Quick Ratio	(Jun 30 2026) 12 Months	(Mar 31 2026) 12 Months	(Dec 31 2025) 12 Months	(Sep 30 2025) 12 Months	(Jun 30 2025) 12 Months
Y / Y Current Liabilities TTM Growth	3.45 %	9.74 %	29.57 %	53.72 %	-0.56 %
Y / Y Cash & cash equivalent TTM Growth	61.37 %	-12.4 %	-52.03 %	-69.69 %	-66.21 %
Quick Ratio TTM	1.51	1.22	0.88	0.63	0.97
Total Ranking TTM	# 3581	# 4145	# 3313	# 3367	# 3367
Seq. Current Liabilities TTM Growth	3.1 %	-7.23 %	-0.1 %	8.27 %	9.37 %
Seq. Cash & cash equivalent TTM Growth	27.75 %	28.68 %	39.38 %	-29.57 %	-30.66 %

Quick ratio ranking by company, industry and sector >> Back to OMER Financial Strength Comparisons >> Go to Compare OMER Quick Ratio to its Competitors

News about Omeros Corporation Quick Ratio

Innovative Frontiers in Hematology Omeros Quest to Transform TA-TMA and PNH Treatments,

Navigating Future Therapeutics: Omeros Corporation s Advances in TA-TMA and PNH In recent months, Omeros Corporation (Nasdaq: OMER) has made significant strides in advancing its therapeutic pipeline. Key developments include the U.S. Food and Drug Administration s (FDA) acceptance of the resubmitted Biologics License Application (BLA) for narsoplimab, intended for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA). Concurrently, Omeros is forging ahead with a Phase 3 clinical trial program for zaltenibart (OMS906), aimed at addressing paroxysmal nocturnal hemoglobinuria (PNH). This article delves into these pivotal projects, examining their potential impact on patient outcomes and the broader field of biopharmaceuticals. FDA Resubmission and PDUFA Date for NarsoplimabNarsoplimab is a human monoclonal antibody targeting mannan-binding lectin-associated serine protease-2 (MASP-2), a critical component of the lectin pathway of the complement system. Its role in the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA) underscores its potential for addressing a significant unmet medical need. TA-TMA is a life-threatening complication that arises post-transplant, characterized by microangiopathic hemolytic anemia, thrombocytopenia, and organ dysfunction.

Omeros Corporation Drives Forward with Promising Phase 3 Trials and Regulatory Strategies for Innovative C...

In an encouraging move for advancing innovative treatments in rare diseases, Omeros Corporation (Nasdaq: OMER) recently announced several significant updates regarding its novel complement inhibitors: zaltenibart and narsoplimab. Based in Seattle, Omeros has been at the forefront of developing transformative therapies that target the complement system, a complex part of the immune system, to address conditions with unmet medical needs. Zaltenibart (OMS906) and the Fight Against Paroxysmal Nocturnal Hemoglobinuria (PNH) Omeros has made substantial headway in its Phase 3 clinical program evaluating zaltenibart for the treatment of paroxysmal nocturnal hemoglobinuria (PNH). PNH is a rare, life-threatening blood disorder characterized by the destruction of red blood cells, leading to severe anemia, fatigue, and life-threatening blood clot formation.

On the trailing twelve months basis OMER Cash & cash equivalent more than doubled by 359.06 % in Q2 2026 year on year, faster than Current Liabilities, this led to increase in in Omeros's Quick Ratio to 1.51, above OMER average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 443 other companies have achieved higher Quick Ratio than Omeros. While Quick Ratio overall ranking has improved so far to 0, from total ranking during the twelve months ending first quarter 2026 at 3136.

Explain Quick Ratio?
How much Cash & cash equivalents OMER�s has?
What are OMER�s Current Liabilities?

TTM Quick Ratio Company Ranking
Within:	No.
Within the Major Pharmaceutical Preparations Industry	# 444
Healthcare Sector	# 912
Within the Market	# 1325

trailing twelve months Quick Ratio Statistics
High	Average	Low
1.63	0.22	0.03
(Sep 30 2022)		(Dec 31 2024)

Companies with similar Quick Ratio in the quarter ending Jun 30 2026, within Major Pharmaceutical Preparations Industry	Quick Ratio	Jun 30 2026 MRQ Cash & cash equivalent	Jun 30 2026 MRQ Current Liabilities
Gain Therapeutics inc	3.81	$ 13.084 Millions	$ 3.434 Millions
Bolt Biotherapeutics Inc	3.79	$ 29.823 Millions	$ 7.867 Millions
Acurx Pharmaceuticals inc	3.72	$ 10.656 Millions	$ 2.865 Millions
Maplight Therapeutics Inc	3.71	$ 71.633 Millions	$ 19.294 Millions
Aptevo Therapeutics Inc	3.47	$ 17.997 Millions	$ 5.188 Millions
Ataibeckley Inc	3.43	$ 168.807 Millions	$ 49.221 Millions
Dogwood Therapeutics inc	3.40	$ 9.628 Millions	$ 2.831 Millions
Tvardi Therapeutics Inc	3.39	$ 30.865 Millions	$ 9.113 Millions
Biomea Fusion Inc	3.32	$ 34.824 Millions	$ 10.483 Millions
Abeona Therapeutics Inc	3.32	$ 146.826 Millions	$ 44.233 Millions
Foghorn Therapeutics Inc	3.31	$ 167.582 Millions	$ 50.579 Millions
Cingulate Inc	3.29	$ 28.403 Millions	$ 8.631 Millions
Unicycive Therapeutics Inc	3.28	$ 61.425 Millions	$ 18.704 Millions
Harmony Biosciences Holdings inc	3.17	$ 667.791 Millions	$ 210.812 Millions
Pulmatrix Inc	3.15	$ 2.168 Millions	$ 0.689 Millions
Nextcure Inc	3.13	$ 20.088 Millions	$ 6.413 Millions
Dianthus Therapeutics Inc	3.13	$ 107.611 Millions	$ 34.389 Millions
Tg Therapeutics Inc	3.02	$ 811.665 Millions	$ 268.493 Millions
Dermata Therapeutics Inc	3.02	$ 4.413 Millions	$ 1.462 Millions
Xilio Therapeutics Inc	2.99	$ 136.040 Millions	$ 45.487 Millions
Cadrenal Therapeutics Inc	2.99	$ 4.476 Millions	$ 1.497 Millions
Zevra Therapeutics Inc	2.99	$ 145.321 Millions	$ 48.632 Millions
Inhibitor Therapeutics Inc	2.95	$ 0.516 Millions	$ 0.175 Millions
Annovis Bio Inc	2.95	$ 18.736 Millions	$ 6.359 Millions
Puma Biotechnology Inc	2.89	$ 144.164 Millions	$ 49.825 Millions
Ptc Therapeutics inc	2.89	$ 2,229.082 Millions	$ 771.068 Millions
Werewolf Therapeutics Inc	2.80	$ 21.987 Millions	$ 7.863 Millions
Alzamend Neuro Inc	2.77	$ 7.591 Millions	$ 2.739 Millions
Scienture Holdings Inc	2.71	$ 8.188 Millions	$ 3.026 Millions
Acadia Pharmaceuticals Inc	2.65	$ 956.474 Millions	$ 361.436 Millions

Date modified: 2026-09-26T07:07:31+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.